ST. GALLEN, Switzerland and STAMFORD, Conn., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the
ST. GALLEN, Switzerland and STAMFORD, Conn., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Medicines Agency’s (EMA) CHMP has recommended approval of Kapruvia ® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. The CHMP opinion is the basis for the European Commission’s final decision regarding marketing authorization for Kapruvia ® . If approved, Kapruvia ® will be the first therapy available in Europe for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients.
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Tuesday, March 1, 2022, at 4:30 p.m. ET to report fourth quarter and full year 2021 financial results and provide a corporate update.
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of

Cara Therapeutics To Host Virtual R&D On March 11

03:06pm, Friday, 18'th Feb 2022 Benzinga
Cara Therapeutics, (NASDAQ:CARA) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on F

Cara Therapeutics To Host Virtual R&D On March 11

03:06pm, Friday, 18'th Feb 2022 Benzinga
Cara Therapeutics, (NASDAQ: CARA ) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 … Full story available on Benzinga.com

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

12:00pm, Friday, 18'th Feb 2022 GlobeNewswire Inc.
Presentation to highlight oral difelikefalin Phase 3 pruritus programs Presentation to highlight oral difelikefalin Phase 3 pruritus programs
Joana Goncalves, MD, chief medical officer of Cara Therapeutics Brian Kim, MD, MTR,

Earnings Preview: Cara Therapeutics (CARA) Q4 Earnings Expected to Decline

08:03pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

04:19pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

03:29pm, Monday, 14'th Feb 2022 Zacks Investment Research
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

04:09pm, Friday, 11'th Feb 2022 Zacks Investment Research
The acquisitions of Vigene Biosciences and Cognate are likely to have a full-quarter favorable impact on Charles River's (CRL) Q4 Manufacturing Support revenues.

Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates

10:35pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

02:46pm, Wednesday, 09'th Feb 2022 Zacks Investment Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases fourth-quarter 2021 results.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE